|

Clemastine Treatment in Individuals With Williams Syndrome

RECRUITINGPhase 3Sponsored by Sheba Medical Center
Actively Recruiting
PhasePhase 3
SponsorSheba Medical Center
Started2024-04-01
Est. completion2024-12
Eligibility
Age6 Years – 30 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06087757

Summary

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.

Eligibility

Age: 6 Years – 30 YearsHealthy volunteers accepted
Inclusion Criteria:

* Individuals with Williams syndrome, which has been confirmed by genetic testing.
* Ages 6-30.
* Normal values in safety variables (e.g. Normal ECG 120-129/80-84).
* No change in psychotropic medications and dosage during the last 4 weeks.
* During the study, no pharmacological change that may impact the study (e.g. ADHD
* medications).

Exclusion Criteria:

* Individuals with another genetic disorder besides Williams syndrome.
* Individuals with Williams syndrome, younger than 6 or older than 30 years old.
* Significant change in normal values in safety variables (e.g. high or low ECG).
* Change in medications and dosage during the last 4 weeks prior the beginning and
* during the study.
* Pregnancy.
* Using addictive substances such as alcohol.

Conditions2

Heart DiseaseWilliams Syndrome

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.